EP3649140A1 - Ef-tu-bindendes metallhaltiges antibiotikum - Google Patents
Ef-tu-bindendes metallhaltiges antibiotikumInfo
- Publication number
- EP3649140A1 EP3649140A1 EP18733554.2A EP18733554A EP3649140A1 EP 3649140 A1 EP3649140 A1 EP 3649140A1 EP 18733554 A EP18733554 A EP 18733554A EP 3649140 A1 EP3649140 A1 EP 3649140A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substituted
- unsubstituted
- branched
- linear
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052751 metal Inorganic materials 0.000 title claims description 13
- 239000002184 metal Substances 0.000 title claims description 12
- 230000003115 biocidal effect Effects 0.000 title description 12
- 239000003446 ligand Substances 0.000 claims abstract description 87
- -1 benzimidazol-2-ylidene Chemical group 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000001580 bacterial effect Effects 0.000 claims abstract description 16
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010061217 Infestation Diseases 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 51
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 239000007787 solid Substances 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 31
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 28
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 23
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 108010090804 Streptavidin Proteins 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 14
- 125000005647 linker group Chemical group 0.000 claims description 14
- 229960002685 biotin Drugs 0.000 claims description 13
- 235000020958 biotin Nutrition 0.000 claims description 13
- 239000011616 biotin Substances 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 108090001008 Avidin Proteins 0.000 claims description 7
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 7
- 125000000129 anionic group Chemical group 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- 150000001540 azides Chemical class 0.000 claims description 6
- CWKYKJQWSSZVDF-UHFFFAOYSA-N n-propyl-1-pyridin-2-ylmethanimine Chemical compound CCCN=CC1=CC=CC=N1 CWKYKJQWSSZVDF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 claims description 6
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 claims description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 3
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 claims description 3
- XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 claims description 3
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims description 3
- VGUWFGWZSVLROP-UHFFFAOYSA-N 1-pyridin-2-yl-n,n-bis(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 VGUWFGWZSVLROP-UHFFFAOYSA-N 0.000 claims description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 3
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 3
- 241000239226 Scorpiones Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 3
- 150000002540 isothiocyanates Chemical class 0.000 claims description 3
- HMMPCBAWTWYFLR-UHFFFAOYSA-N n-pyridin-2-ylpyridin-2-amine Chemical compound C=1C=CC=NC=1NC1=CC=CC=N1 HMMPCBAWTWYFLR-UHFFFAOYSA-N 0.000 claims description 3
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 3
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 150000002826 nitrites Chemical class 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003567 thiocyanates Chemical class 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- ADLVDYMTBOSDFE-UHFFFAOYSA-N 5-chloro-6-nitroisoindole-1,3-dione Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC2=C1C(=O)NC2=O ADLVDYMTBOSDFE-UHFFFAOYSA-N 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 62
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
- 238000005481 NMR spectroscopy Methods 0.000 description 39
- 239000011575 calcium Substances 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 21
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 20
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 20
- 235000014469 Bacillus subtilis Nutrition 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 238000005102 attenuated total reflection Methods 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000003480 eluent Substances 0.000 description 16
- 238000000132 electrospray ionisation Methods 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical class [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- 108010026552 Proteome Proteins 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- QLNAVQRIWDRPHA-UHFFFAOYSA-N iminophosphane Chemical compound P=N QLNAVQRIWDRPHA-UHFFFAOYSA-N 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- PLBXFYFBJMNSHS-UHFFFAOYSA-N 2-azidoaniline Chemical compound NC1=CC=CC=C1N=[N+]=[N-] PLBXFYFBJMNSHS-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 241000192125 Firmicutes Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 108010085026 GE 2270 A Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000004949 mass spectrometry Methods 0.000 description 7
- 229910052702 rhenium Inorganic materials 0.000 description 7
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010058432 Chaperonin 60 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 108010081596 nocathiacin I Proteins 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- FFLJEMWVYVKPDW-UMNFMQIXSA-N chembl263049 Chemical compound O([C@H]1[C@H]2OCC3=C(N(C=4C=CC=C(C3=4)COC1=O)O)C(=O)OC[C@H]1C=3SC=C(N=3)C3=NC(=C(O)C=C3C=3SC=C(N=3)C(=O)N[C@H](C(=O)N/C(C=3SC=C(N=3)C(=O)N[C@@H]2C=2SC=C(N=2)C(=O)N1)=C(C)/OC)[C@@H](C)O)C=1SC=C(N=1)C(=O)NC(=C)C(N)=O)[C@H]1C[C@](C)(O)[C@H](N(C)C)[C@H](C)O1 FFLJEMWVYVKPDW-UMNFMQIXSA-N 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- FFLJEMWVYVKPDW-VCUUIXPJSA-N nocathiacin I Natural products COC(=C1NC(=O)[C@@H](NC(=O)c2csc(n2)c3cc(O)c(nc3c4csc(n4)[C@@H]5COC(=O)c6c7CO[C@@H]([C@H](NC(=O)c8csc1n8)c9nc(cs9)C(=O)N5)[C@H](O[C@H]%10C[C@](C)(O)[C@@H]([C@H](C)O%10)N(C)C)C(=O)OCc%11cccc(c7%11)n6O)c%12nc(cs%12)C(=O)NC(=C)C(=O)N)[C@@H](C)O)C FFLJEMWVYVKPDW-VCUUIXPJSA-N 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HIKRJHFHGKZKRI-UHFFFAOYSA-N 2,4,6-trimethylbenzaldehyde Chemical compound CC1=CC(C)=C(C=O)C(C)=C1 HIKRJHFHGKZKRI-UHFFFAOYSA-N 0.000 description 4
- DHDHJYNTEFLIHY-UHFFFAOYSA-N 4,7-diphenyl-1,10-phenanthroline Chemical compound C1=CC=CC=C1C1=CC=NC2=C1C=CC1=C(C=3C=CC=CC=3)C=CN=C21 DHDHJYNTEFLIHY-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 230000006287 biotinylation Effects 0.000 description 4
- 238000007413 biotinylation Methods 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004807 desolvation Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 108010063460 elongation factor T Proteins 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000006862 quantum yield reaction Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000588626 Acinetobacter baumannii Species 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010006519 Molecular Chaperones Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 150000001615 biotins Chemical class 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000295 emission spectrum Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000004474 heteroalkylene group Chemical group 0.000 description 3
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 125000002524 organometallic group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KXZQYLBVMZGIKC-UHFFFAOYSA-N 1-pyridin-2-yl-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CNCC1=CC=CC=N1 KXZQYLBVMZGIKC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 241000276408 Bacillus subtilis subsp. subtilis str. 168 Species 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- JMDULECOHIXMNX-UHFFFAOYSA-N GE2270A Chemical compound N1C(=O)CNC(=O)C(=C(S2)COC)N=C2C(C(C)C)NC(=O)C(=C(S2)C)N=C2C(CC(=O)NC)NC(=O)C(N=2)=CSC=2C2=CC=C(C=3SC=C(N=3)C=3OCC(N=3)C(=O)N3C(CCC3)C(N)=O)N=C2C(N=2)=CSC=2C(N=2)=CSC=2C1C(O)C1=CC=CC=C1 JMDULECOHIXMNX-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010022337 Leucine Enkephalin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002527 isonitriles Chemical class 0.000 description 2
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical group 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OTFSUKUZAUQRHP-UHFFFAOYSA-N 2-azido-N-benzylaniline Chemical compound N(=[N+]=[N-])C1=C(NCC2=CC=CC=C2)C=CC=C1 OTFSUKUZAUQRHP-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 201000008000 3-methylcrotonyl-CoA carboxylase deficiency Diseases 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241001430149 Clostridiaceae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000025053 Escherichia coli DSM 30083 = JCM 1649 = ATCC 11775 Species 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102100023737 GrpE protein homolog 1, mitochondrial Human genes 0.000 description 1
- 241000207155 Heliobacterium Species 0.000 description 1
- 101000829489 Homo sapiens GrpE protein homolog 1, mitochondrial Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 238000004639 Schlenk technique Methods 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000186339 Thermoanaerobacter Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CENDTHIEZAWVHS-UHFFFAOYSA-N carbon monoxide;cyclopenta-1,3-diene;manganese Chemical compound [Mn].[O+]#[C-].[O+]#[C-].[O+]#[C-].C=1C=C[CH-]C=1 CENDTHIEZAWVHS-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- PVDGXEIFXYECGU-UHFFFAOYSA-N n-azidoaniline Chemical compound [N-]=[N+]=NNC1=CC=CC=C1 PVDGXEIFXYECGU-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 150000003281 rhenium Chemical class 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 1
- FZHCFNGSGGGXEH-UHFFFAOYSA-N ruthenocene Chemical compound [Ru+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 FZHCFNGSGGGXEH-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108010018381 streptavidin-binding peptide Proteins 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000005287 template synthesis Methods 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000001161 time-correlated single photon counting Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000001392 ultraviolet--visible--near infrared spectroscopy Methods 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the present invention is in the field of medicinal chemistry and relates to an N-heterocyclic carbene (NHC) Re (I) complex with an unsubstituted or substituted benzimidazol-2-ylidene ligand and its use, in particular in a pharmaceutical composition, as a medicament and for the treatment of a bacterial infection or a bacterial infestation. Further, the present invention relates to a method for producing an N-heterocyclic carbene (NHC) Re (I) complex and to a method for identifying a biomolecule that interacts with an N-heterocyclic carbene (NHC) Re (I) complex.
- N-heterocyclic carbene (NHC) complexes with a wide range of transition metals and ligand structures has led to spectacular insights and numerous applications, especially in catalysis and photophysics.
- Re (I) complexes with either monodentate 7 "14 or multidentate 15" 21 N-heterocyclic carbene ligands, very little is known about their biological properties, and studies focus primarily on potential applications OLEDs or catalysts. 22 "23 This is particularly surprising since Re (I), with its structural diversity, redox properties, and availability of the radioactive analogues 186 Re, 188 Re, and 99m Tc, offers tremendous potential for diagnostic or therapeutic purposes. " 24 It is known in that Re (I) - Complexes may have antibacterial activity.
- the antibacterial compounds already described are very large and consist of a peptide-nucleic acid backbone with an alkyne side chain substituted with a cymantrene, a (dipicolyl) Re (CO) 3 unit and either a ferrocene (FcPNA) or a ruthenocene (RcPNA ).
- a molecule with a lower molecular weight would be desirable.
- the object described above is achieved by the complex of the present invention.
- the inventors of the present invention have surprisingly found in a series of experiments that an N-heterocyclic carbene (NHC) Re (I) complex with an unsubstituted or substituted benzimidazol-2-ylidene ligand, as described herein, has a high antimicrobial activity against Gram-positive bacteria Has. Furthermore, it has been found that the complexes described herein have a different mode of action compared to other antibiotics which target the same target, such as nocathiacin I, GE2270A and kirromycin. These properties allow the use of structurally and mechanistically novel antibiotics and increase the likelihood that the formation of resistance to the complexes according to the invention will be very delayed.
- the present invention is directed to a complex having the structure of formula (I)
- R 1, R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of H, linear or branched, substituted or unsubstituted alkyl, linear or branched, substituted or unsubstituted heteroalkyl, linear or branched, substituted or unsubstituted alkenyl , linear or branched, substituted or unsubstituted heteroalkenyl, linear or branched, substituted or unsubstituted alkynyl, linear or branched, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, linear or branched, substituted or unsubstituted alkylaryl, linear or branched, substituted or unsubstituted heteroalkylaryl, each
- Li, L 2 , L 3 , L 4 and L 5 are independently metal coordinating ligands selected from the group consisting of neutral ligands, anionic ligands and mixed ligands.
- Li, L 2 , L 3 , L 4 and L 5 are independently selected from the group consisting of halo, carbonyl, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, sulfide, thiocyanate, nitrate, azide, fluoride, hydroxide ion, H 2 0 , Nitrite, isothiocyanate, acetonitrile, pyridine, ammonia, triphenylphosphine, cyanide, carbon monoxide, linear or branched, substituted or unsubstituted alkene having up to 20 carbon atoms, benzene, cyclopentadienyl, nitrosyl, oxo ligand, sulfites, tricyclohexylphosphane, trimethylphosphane, tri (o -tolyl) phosphine, cycloheptatriene, carbon dioxide; or
- each X is independently H or a linear or branched alkyl having up to 20 carbon atoms
- LI, L2, L3, L4 and L5, which are not linked to other metal coordinating ligands, are defined as in a).
- L 4 and L 5 are linked to form a molecule and are selected from the group consisting of
- each X is independently H or a linear or branched alkyl having up to 20 carbon atoms.
- L 4 and L 5 are selected from the group consisting of
- Ri is H, CH 2 -phenyl or
- R 2 is H.
- R3-R6 are H; and / or L1-L3 are CO.
- the invention is directed to a complex according to the invention, wherein a) Ri is H, CH 2 -phenyl or
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- R 2 is H
- R3-R5 are H; and L1-L3 are CO; and
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- Ri is H, CH 2 -phenyl or
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- L4 and L5 are linked to build.
- a second aspect of the invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising an inventive and a pharmaceutically acceptable carrier or excipient.
- the present invention is directed to a complex of the invention for use as a medicament.
- a fourth aspect of the invention is directed to a complex of the invention for use in the treatment of a bacterial infection or a bacterial infestation, wherein the bacterial infection or the bacterial infestation is caused by a Gram-positive bacterium.
- the Gram-positive bacterium is selected from the group consisting of Bacillus or Staphylococcus.
- the present invention is directed to a process for the preparation of a complex having the structure of formula (II)
- Ri, R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of
- Heteroalkynyl substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, linear or branched, substituted or unsubstituted alkylaryl, linear or branched, substituted or unsubstituted heteroalkylaryl, wherein each of these groups has up to 20 carbon atoms; and
- Li, L 2, L3, L4 and L5 are independently metal-coordinating ligands are selected from the group consisting of neutral ligands, anionic ligand and mixed ligand; full
- a sixth aspect of the invention is directed to a method of identifying a molecule that interacts with a complex of the invention comprising a) providing a complex of the invention wherein R5 is a linker group, and b) immobilizing the complex of a) on a solid support, wherein the solid support binds the complex via the linker group;
- the linker group
- Biotin and the solid carrier comprises avidin and / or streptavidin.
- Figure 1 Scheme of the preparation of the neutral benzimidazol-2-ylidene-3a - 3c complexes.
- Figure 2 Possible mechanism of formation of the Re (I) -Carben complex 3 a.
- Figure 3 Ligand exchange reactions of the complexes 3a, 3b and 3c.
- FIG. 4 ORTEP representation of the compounds 3a (a) and 3c (b) (Ellipsoids are shown with 50% probability of residence).
- FIG. 5 ORTEP representation of the bipyridine complexes 4a (a), 4b (b) and 4c (c) (Ellipsoids are shown with 50% probability of residence). For reasons of clarity, the counterion bromide was not included in the figure.
- Figure 6 Overview of the photophysical properties of the complexes 4a-7a.
- Figure 7 Normalized absorption (left) and emission spectra (right) of the compounds 4a, 5a, 6a and 7a in acetonitrile.
- FIG. 10 The elongation factor Tu of B. subtilis binds to immobilized biotin-DS50.
- Biotin-DS50 was immobilized with Strep-Tactin® Sepharose and incubated with B. subtilis protein extract. Unbound proteins (flow through) were discarded and the sepharose was washed (wash fraction) before proteins bound to biotin-DS50 were eluted by heating in SDS-PAGE sample buffer.
- Strep-Tactin® Sepharose was incubated with biotin, DS50 or without complex (w / o) for control. Proteins specifically binding to biotin-DS50 were identified by mass spectrometry.
- FIG 11 The elongation factor Tu and GroEL from B. subtilis co-elute with DS50.
- DS50 was incubated with B. subtilis cytosolic protein extract or with buffer as control (free compound). The extract was separated by native ion exchange chromatography and elution profiles of the free and protein bound DS50 were reconstituted by mass spectrometry. Proteins in fractions containing protein-bound DS50 were identified. The elution profiles of elongation factor Tu and GroEL are shown.
- Figure 12 Proteompro col of B. subtilis after treatment with DS50 or biotin-DS50.
- Logarithmically growing B. subtilis cells were grown stressed or untreated by treatment with antibiotics as a control. Newly synthesized proteins were radiolabeled and the proteins were separated by 2D polyacrylamide gel electrophoresis. Radiolabelled proteins were detected by phosphoscreens and phosphoscanner, and the digitized gel images of the untreated controls (green) were overlaid with gel images of the antibiotic treatment (red). High, low and unregulated proteins appear in red, green and yellow, respectively. Marker proteins that were at least two-fold upregulated in all biological replicates in response to antibiotic treatment and identified by mass spectrometry are indicated by arrows.
- FIG. 13 Proteome profile of B. subtilis after treatment with DS50 or antibiotics known to be associated with the translation activity of Elongation factor Tu interfere (nocathiazine I, GE2270 A and kirromycin).
- Tu interfere nocathiazine I, GE2270 A and kirromycin.
- Logarithmically growing B. subtilis cells were stressed by treatment with antibiotics or left untreated for control. Newly synthesized proteins were radioactively labeled and the proteins were separated by 2D polyacrylamide gel electrophoresis. Newly synthesized proteins were displayed in false color images as described above.
- the untreated controls green were overlaid with gels of the antibiotic treatment (red). High, low and unregulated proteins appear in red, green and yellow, respectively. Marker proteins that were at least two-fold upregulated in all biological replicates in response to antibiotic treatment were identified by mass spectrometry and are indicated by arrows
- the inventors of the present invention have surprisingly found, structurally and mechanistically, new antibiotics that allow selective treatment of Gram-positive bacteria.
- the present invention is directed to a complex having the structure of the formula (I)
- R 1, P 2, Pv 3, P 4, P 5 and R 6 are independently selected from the group consisting of H, linear or branched, substituted or unsubstituted alkyl, linear or branched, substituted or unsubstituted heteroalkyl, linear or branched, substituted or unsubstituted alkenyl, linear or branched, substituted or unsubstituted heteroalkenyl, linear or branched, substituted or unsubstituted alkynyl, linear or branched, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, linear or branched, substituted or unsubstituted Alkylaryl, linear or branched, substituted or unsubstituted heteroalkylaryl, wherein each of these groups has
- Li, L 2 , L 3 , L 4 and L 5 are independently metal coordinating ligands selected from the group consisting of neutral ligands, anionic ligands and mixed ligands.
- rhenium or "Re”, as used interchangeably herein, denotes a chemical element having atomic number 75. In the Periodic Table of the Elements, rhenium is in the 7th subgroup (Group 7) or manganese group. It is a very rare, silvery white, heavy transition metal.
- alkyl alone or as part of another substituent, unless otherwise specified, means a linear (ie unbranched) or branched chain or combination thereof which is fully saturated and may include di- and polyhydric radicals Alkyls are more closely identified by the number of carbon atoms present (eg, C1-C10 represents one to ten carbons), and preferred are alkyls of up to 20, up to 15, up to 10, or up to 5 carbon atoms.
- n-pentyl n Hexyl, n-heptyl, n-octyl and the like.
- alkylene denotes a bivalent radical derived from an alkyl, as exemplified but not limited to -CH 2 CH 2 CH 2 CH 2 -.
- an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
- a “lower alkyl” or “lower alkylene” is a shorter alkyl or alkylene group as defined in U.S. Pat Generally has eight or fewer carbon atoms.
- heteroalkyl denotes a stable linear or branched or cyclic hydrocarbon radical or combinations thereof consisting of at least one carbon atom and at least one heteroatom selected from A group consisting of O, N, P, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized
- the heteroatom (s) O, N, P and S and Si may be attached any internal position of the heteroalkyl group or at the site where the alkyl group is attached to the rest of the molecule Examples include, but are not limited to, -CH 2 --CH 2 -O-CH 3 , -CH 2 - CH 2 -NH-CH 3 , -CH 2 -CH 2 -N (CH 3 ) 2 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 , -SCHO-CH 2 -S (0 ) 2 -CH
- heteroalkylene by itself or as part of another substituent, a radical derived from heteroalkyl divalent radical such as is exemplified, but not limited to - CH 2 -CH 2 -CH-CH 2 -CH 2 - and
- heteroatoms may also adopt one or both of the chain termini (eg, alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like)
- alkylene and -CH 2 -CH 2 -S-CH 2 -CH 2 -NH-CH 2 - Heteroalkylene linking groups do not indicate orientation of the linking group by the direction in which the formula of the linking group is written
- the formula -C (O) 2 R- means both -C (O) 2 R
- heteroalkyl groups include, as used herein, those groups which in the rest of the molecule through a heteroatom, such as -C (0) R *, -C (0) NR, -NR'R " , -OR * , - SR 'and / or -S0 2 R'.
- heteroalkyl followed by recitations of specific heteroalkyl groups such as -NR'R "or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups will be referred to The term “heteroalkyl” should therefore not be interpreted herein as exclusive specific heteroalkyl groups such as - NR'R “or the like.
- cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, unless otherwise indicated, represent cyclic versions of
- heterocycloalkyl a heteroatom may be the
- cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1- (l, 2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl , Tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl and the like.
- a “cycloalkylene” and “heterocycloalkylene” refers to a bivalent radical derived from cycloalkyl or heterocycloalkyl, respectively.
- halogen or halo, by itself or as part of another substituent, unless otherwise specified, mean a fluorine, chlorine, bromine or iodine atom.
- terms such as “haloalkyl” are intended to include monohaloalkyl and polyhaloalkyl
- halo (C 1 -C 4) alkyl trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl and the like is, but is not limited to this.
- aryl unless otherwise indicated, means a polyunsaturated aromatic hydrocarbon substituent which may be a single ring or multiple rings (preferably 1 to 3 rings) fused together or covalently linked.
- Heteroaryl refers to aryl groups (or rings) containing from one to four heteroatoms selected from N, O and S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom (s) is optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule by a carbon or heteroatom.
- Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2 -Oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl , 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-is
- aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
- “Arylene” and “heteroarylene” refers to a bivalent radical derived from an aryl and heteroaryl.
- arylalkyl is intended to include those radicals in which an aryl group is attached to an alkyl group (eg, benzyl, phenethyl, pyridylmethyl, and the like).
- heteroarylalkyl includes the groups described above wherein one or more carbon atoms of the alkyl or aryl moiety (eg, a methylene group), for example, by an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3- (1-naphthyloxy) propyl, and the like).
- heteroalkyl When a heteroalkyl, heterocycloalkyl or heteroaryl contains a certain number of members (e.g., “3 to 7 membered"), the term “member” refers to a carbon or heteroatom.
- oxo as used herein means an oxygen double bonded to a carbon atom.
- each of the R groups is independently selected, for example, each of R ', R ", R'" and R “" groups.
- R 'and R "are attached to the same nitrogen atom they may be combined with the nitrogen atom to form a 4-, 5-, 6- or 7-membered ring, for example, -NR'R" 1-pyrrolidinyl and 4-morpholinyl include, but not on be limited.
- alkyl is intended to include groups that include carbon groups attached to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3) and acyl ( for example -C (O) CH 3 , -C (O) CF 3 , -C (O) CH 2 OCH 3 and the like).
- haloalkyl e.g., -CF 3 and -CH 2 CF 3
- acyl for example -C (O) CH 3 , -C (O) CF 3 , -C (O) CH 2 OCH 3 and the like.
- two substituents on adjacent ring atoms may be combined to form a cyclic group which may be saturated, unsaturated or aromatic and is selected from aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, all of which may be as described above the respective groups defined to be substituted.
- heteroatom or "ring heteroatom” means oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
- the alkenyl group may be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, aryl, Heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfoxo or thiol, as described herein.
- Examples of cycloalkenyl groups include cyclopropenyl , Cyclo-butenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbornenyl and the like, but the cycloalkenyl group may be substituted or unsubstituted
- the cycloalkenyl group may be substituted with one or more groups, including, but not limited to, alkyl, cycloalkyl , Alkoxy, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide,
- alkynyl is a hydrocarbyl group of 2 to 20 carbon atoms having a structural formula containing at least one carbon-carbon triple bond
- the alkynyl group may be unsubstituted or substituted with one or more groups. including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, esters, ethers, halide, hydroxy, ketone, azide, nitro, silyl, sulfoxo or thiol, as herein described.
- ligand or "metal coordinating ligand”, as used interchangeably herein, is an atom or molecule which binds to a central metal ion via coordinative bonding (also known as “dative bonding”) ") can.
- the coordinative binding is due to the Lewis character of the binding partners involved: ligands are Lewis bases (electron pair donors), metal ions Lewis acids (electron pair acceptors).
- Ligands are classified according to their charge: negatively charged ligands are abbreviated as X-type or anionic ligands (example halides), while neutral ligands are abbreviated as L-type (example phosphines).
- Ligands containing both a negative charged portion and a neutral portion are referred to herein as mixed ligands or mixed-loaded ligands.
- the denticity indicates how many bonds to the central atom can form a ligand.
- Ligands that form only one bond to the central atom become monodentate or called monodentate.
- Ammonia (NH3, referred to in the complex as ammine) is, for example, a monodentate ligand: H3N- M.
- Li, L 2 , L 3 , L 4 and L 5 are each to be understood as a ligand.
- the coordination environment of the rhenium atom in the complexes of the invention may be varied by various combinations of monodentate ligands and / or chelating ligands.
- the combination is a bidentate ligand and three monodentate ligands.
- Li, L 2 , L 3 , L 4 and L 5 are independently selected from the group consisting of halo, carbonyl, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, sulfide, thiocyanate, nitrate, azide, fluoride, hydroxide ion, H 2 0, nitrite, isothiocyanate, acetonitrile, pyridine, ammonia, triphenylphosphine, cyanide, carbon monoxide, linear or branched, substituted or unsubstituted alkene having up to 20 carbon atoms, benzene, cyclopentadienyl, nitrosyl, oxo ligand, sulfites, tricyclohexylphosphane, trimethylphosphane, tri (o-tolyl) phosphine, cycloheptatriene, carbon dioxide; or
- each X is independently H or a linear or branched alkyl having up to 20 carbon atoms
- the term "linked to form a molecule” refers to the compound that provides at least two of the five ligands on the coordinated rhenium atom, Preferably, these linked ligands are linked indirectly via one or more atoms, all of which In particular, it is preferred that two ligands are tertiary nitrogen atoms, each bonded via double bonds to carbon atoms C x and C y , with C x and C y directly via a single bond Furthermore, the atoms C x and C y may be part of an aryl system described above.
- L 4 and L 5 are linked to form a molecule and are selected from the group consisting of
- each X is independently H or a linear or branched alkyl having up to 20 carbon atoms.
- L 4 and L 5 are selected from the group consisting of
- R 1 is H, CH 2 -phenyl or
- R 2 is H.
- R? -RO? H; and / or L1-L3 are CO.
- the invention is directed to a complex according to the invention, wherein a) Ri is H, CH 2 -phenyl or
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- R 2 is H
- R3-R6 are H; and L1-L3 are CO; and
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- Ri is H, CH 2 -phenyl or
- R 2 is H
- R3-R6 are H
- L1-L3 are CO;
- R 2 is H
- R3-R5 are H
- L1-L3 are CO; and L 4 and L 5 are linked to each other to build.
- a second aspect of the invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising a and a pharmaceutically acceptable carrier or excipient according to the invention.
- a “pharmaceutical composition” refers to a mixture of one or more of the compounds described herein or physiologically / pharmaceutically acceptable salts or prodrugs thereof with other chemical components such as physiologically / pharmaceutically acceptable carriers and excipients / excipients Composition is to facilitate the administration of a compound to an organism.
- a "physiologically / pharmaceutically acceptable carrier” refers to a carrier or diluent that does not cause significant irritation of an organism and does not abrogate the biological activity and properties of the administered compound.
- a “pharmaceutically acceptable excipient (s)” refers to an inert substance added to a pharmaceutical composition to further facilitate the administration of a compound.
- examples without limitation include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
- salts refers to those salts which retain the biological activity and properties of the parent compound
- Such salts include, but are not limited to: (1) an acid addition salt obtained by reacting the free base of the starting compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid and perchloric acid and the like or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid , Tartaric acid, citric acid, succinic acid or malonic acid and the like, preferably hydrochloric acid or (L) - Lactic acid; or (2) salts formed when an acidic proton present in the starting compound is replaced by either a metal ion such as an alkali metal ion such as sodium or potassium, an alka
- compounds of the invention will be metabolized by enzymes in the body of the organism, such as a human, to produce a metabolite having the desired functionality. Such metabolites are within the scope of the present invention.
- Treatment and “treating” refer to a method of alleviating or eliminating a disease or disorder and / or its associated symptoms.
- Organism refers to any animal that consists of at least one cell
- a living organism can be as simple as, for example, a single eukaryotic cell or as complex as a mammal, including a human.
- “Therapeutically effective amount” refers to the amount of compound administered which will, to some degree, relieve one or more of the symptoms of the disorder being treated.
- the present invention is directed to a complex of the invention for use as a medicament.
- drug or “drug” as used interchangeably herein is intended to include any substance (ie, a compound or composition of matter) which, when administered to an organism (human or animal), has a desired pharmacological and / or or physiological effect by local injection and / or systemic measures.
- the term therefore includes substances traditionally considered as drugs, drugs and bioactive agents as well as biopharmaceuticals (eg, peptides, hormones, nucleic acids, gene constructs, etc.) that are typically used to treat a number of conditions that are broadly understood are defined as diseases, disorders, infections and the like.
- a fourth aspect of the invention is directed to a complex of the invention for use in the treatment of a bacterial infection or a bacterial infestation, wherein the bacterial infection or the bacterial infestation is caused by a Gram-positive bacterium.
- infection refers to the presence of bacteria in or on a subject whose inhibition would result in benefit to the subject.
- infection also refers to the normal bacterial flora whose inhibition is not desired.
- infection or “bacterial infection” also includes infections caused by Gram-positive and An infection can also be understood as a collection of bacteria in a subject, such a collection of bacteria being absent or in a significantly reduced amount in a healthy reference subject.
- bacterial infestation refers to an accumulation of bacteria on or in the body of a subject without directly altering the tissue or body part on or in which the bacterial accumulation is located, or the bacteria
- tissue or body part may, for example, but without limiting the invention, be hair, skin or teeth.
- the Gram-positive bacterium is selected from the group consisting of Bacillus or Staphylococcus.
- Bacteria, eubacteria are bacteria that have a Gram-positive cell wall (bacterial cell wall,
- Subgroups Bacillus ILactobacillus, Streptococcus, Heliobacterium, Mollicutes (cell wallless bacteria and relatives) and the Synthrophomonas / Thermoanaerobacter line and 2) the high G + C forms.
- the first main line most single-celled, cocci-shaped, cell-wall-free bacteria as well as the non-spore-forming rod-shaped species and the spore formers are classified (Clostridiaceae).
- the second major line includes the actinomycetes and related organisms, including the coryneform bacteria, mycobacteria and nocardia.
- Gram-positive bacteria include, but are not limited to, the following classes: staphylococci, streptococci, pneumococci, enterococci, bacilli, clostridia, cory neb acter ium, listeria and actinomyces.
- the present invention is directed to a process for the preparation of a complex having the structure of formula (II)
- R 1, R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of H, linear or branched, substituted or unsubstituted alkyl, linear or branched, substituted or unsubstituted heteroalkyl, linear or branched, substituted or unsubstituted alkenyl, linear or branched, substituted or unsubstituted heteroalkenyl, linear or branched, substituted or unsubstituted alkynyl, linear or branched, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, linear or branched, substituted or unsubstituted alkylaryl, linear or branched, substituted or unsubstituted heteroalkylaryl wherein each of these groups has
- Li, L 2, L3, L4 and L5 are independently metal-coordinating ligands are selected from the group consisting of neutral ligands, anionic ligand and mixed ligand; full contacting a compound having the structure of the formula (III)
- contacting generally refers to the access of one component, reagent, analyte or sample to another.
- contacting may involve mixing a solution.
- This solution which includes a component, reagent, analyte or sample, may also include another component or reagent such as dimethylsulfoxide (DMSO), a detergent or human serum albumin, which may include mixing, interaction, ingestion or otherwise physical or chemical phenomenon that is beneficial facilitates.
- DMSO dimethylsulfoxide
- a detergent or human serum albumin a detergent or human serum albumin
- the compounds (III) and (IV) are dissolved under inert gas (N 2 ) in a molar ratio of 1: 1 in toluene or THF and stirred for 24 hours at room temperature.
- the solvent is removed in vacuo and the crude product (compound (II)) is purified by column chromatography on silica gel.
- the compound (II) can be further reacted to compound (I).
- Corresponding reactions are known to the person skilled in the art.
- a sixth aspect of the invention is directed to a method of identifying a molecule that interacts with a complex of the invention comprising a) providing a complex of the invention wherein R 5 is a linker group, and b) immobilizing the complex of a) a solid support, wherein the solid support binds the complex via the linker group;
- Biotin and the solid carrier comprises avidin and / or streptavidin.
- immobilizing refers to the attachment or adherence of one or more biomolecules to the activated surface of a solid support, including attachment or adhesion to the activated inner surface of the support if it is porous.
- Solid support refers to any solid surface to which the compounds of the invention can be attached, such as latex beads, dextran beads, polystyrene surfaces, polypropylene surfaces, polyacrylamide gel, gold surfaces, glass surfaces, and silicon wafers.
- linker group refers to any agent or molecule that links the compounds of the invention and the solid support In preferred embodiments, all molecular bonds are within both the linker group and the compounds of the invention and the solid Carrier covalent and stable under the conditions of the identification method.
- avidin as used herein means any biotin-binding compound such as avidin, streptavidin, any modified or mutated avidin produced by Laboratory techniques that are capable of binding biotin or a functional equivalent of biotin. Streptavidin is a specific subtype of avidin.
- streptavidin as used herein includes wild-type streptavidin, streptavidin muteins, and streptavidin-like polypeptides unless otherwise specified in a particular case.
- wild-type streptavidin wt-streptavidin
- Streptavidin muteins are polypeptides that differ from the sequence of wild-type streptavidin by one or more amino acid substitutions, deletions or additions and that have the binding properties of wt-streptavidin Streptavidin-like polypeptides and streptavidin muteins are polypeptides that are substantially immunologically equivalent to wild-type streptavidin and, in particular, can bind biotin, biotin derivative or biotin analogs with the same or different affinity as wt-streptavidin -like polypeptides or streptavidin-muteins may contain amino acids that are not Part of the wild-type streptavidin are or may contain only part of the wild-type streptavidin.
- streptavidin also includes streptavidin-tetramers and streptavidin-dimers, in particular streptavidin-homotetramers, streptavidin-homodimers, streptavidin-heterotetramers and streptavidin-heterodimers.
- Each subunit normally has a binding site for biotin or biotin analogs or for streptavidin-binding peptides.
- streptavidins or streptavidin muteins are described in WO 86/02077, DE 19641876 Al, U.S. Pat. Pat. Nos. 6,022,951, WO 98/40396 and WO 96/24606.
- At least 1 refers to 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 100 or more, or 1000 or more.
- ⁇ is the quantum yield
- ⁇ stands for the refractive index of the solvent
- G is determined by plotting the absorption of a series of dilutions (absorbance ⁇ 0, 1) is determined against the integrated emission intensity G is obtained as a gradient of a linear approximation of the plotted data.
- MIC Minimum inhibitory concentrations
- Bacillus subtilis DSM 402, Staphylococcus aureus DSM 20231 and Staphylococcus aureus ATCC 43300 MRSA.
- Gram-negative strains used were Escherichia coli DSM 30083, Acinetobacter baumannii DSM 30007 and Pseudomona aeruginosa DSM 50071.
- E. coli, A. baumannii, S. aureus and B. subtilis were grown in Mueller-Hinton liquid medium, while P. aeruginosa was grown in Mueller-Hinton II liquid medium.
- the compounds were stored in DMSO and in solutions of 10 mg / ml.
- Serial dilution was performed on a Tecan Freedom Evo 75 liquid handling workstation (final concentrations 0.5 to 512 ⁇ g / ml). Serial dilutions were inoculated with 5x10 5 bacteria / ml from late-exponential cultures (total volume 200 ⁇ per well). Cells were incubated at 37 ° C for 16-18h. The lowest concentration that prevents visible bacterial growth is expressed as MIC.
- Trimethylbenzyl) (aniline (272 mg, 1 mmol) and PPh 3 265 mg, 1.02 mmol) is carried out.
- Rhenium complexes 3a-3c (1 eq.) And the corresponding bisimine ligand (1.05 eq.) are dissolved / suspended in toluene and stirred at 100 ° C for 4 h. After cooling to ambient temperature, the yellowish precipitate is isolated by filtration, washed thoroughly with cold ether and dried in vacuo to obtain the product in high purity. In cases where the products do not precipitate immediately, cold ether can be added to facilitate precipitation.
- Figure 7b The general procedure was performed with complex 3b (30 mg, 0.05 mmol) and bathophenanthroline (20 mg, 0.06 mmol). The product was obtained as a yellow solid (39 mg, 96%). C 4 iH 2 8N 4 0 3 ReBr (890.81 g / mol).
- lysis buffer 100 mM Tris / HCl, pH 8.1 mM dithiothreitol (DTT), 1 mM ⁇ -mercaptoethanol, 0.2 mg / ml DNase, 0.2 mg / m
- the material was mixed with 500 ⁇ cell lysate, and either no additional compound, 200 ⁇ biotin or 200 ⁇ DS50 as controls or with 200 ⁇ biotin-DS50. After incubation on ice for 3 h, the cell lysate was removed by centrifugation and the material washed four times with wash buffer. Specifically bound proteins were eluted with 50 ⁇ M SDS-PAGE sample buffer (50 mM Tris / HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.1% bromophenol blue) at 96 ° C for 15 min. Proteins were separated with 12% SDS gels according to standard protocols and visualized by a Ruthenium (II) tris (4,7-diphenyl-l, 10-phenantrolindisulfonat) staining (RuBPS).
- RuBPS Ruthenium tris (4,7-diphenyl-l, 10-phenantrolindisulfonat
- the cells were resuspended in 10 ml lysis buffer (20 mM Tris / HCl, pH 7.5, 0.2 mg / ml DNase, 0.2 mg / ml RNase, 0.2 mg / ml lysozyme, 1 mM DTT, 1 mM ⁇ -mercaptoethanol) with the aid of a French Press digested (900 psi, 4 ° C) and cell debris centrifuged (43,000 g, 30 min, 4 ° C).
- the supernatant was treated with Amicon ® Ultra centrifuge filters concentrated (3 kDa cut-off size, Sigma Aldrich), adjusted to a protein concentration of 21.6 mg / ml in 50% glycerol, and as aliquots of 300 ⁇ at -80 ° C storage.
- buffer B buffer A, with 1.5 M NaCl
- buffer B buffer A, with 1.5 M NaCl
- 90 minutes, 60% B 95 minutes, 100% B
- 115 minutes, 100% B 120 min, 0% B; 125 min, 0% B with a flow rate of 0.25 ml / min.
- Fractions were collected in 96-well microtiter plates for 96 min (1 min / fraction).
- buffer B (0.1% formic acid in acetonitrile) were used as eluents for the chromatography.
- the UPLC was operated at a flow rate of 5 ⁇ / min and a column temperature of 40 ° C with the following gradient: initial, 5% buffer B; 15 minutes, 99% B; 16 minutes, 99% B; 17 min, 5% B; 25 min, 5% B.
- Spectra were recorded in positive sensitivity mode with the following settings: capillary voltage, 3 kV; Cone voltage, 30 V; Source temperature, 100 ° C; Conical gas flow, 50 L / h; Desolvation Fuse, 500 L / h; Desolvation temperature, 150 ° C.
- MSMS spectra of precursor mass 571.1 were recorded in the mass range of 50-1200 m / z with a scan time of 1 s and a collision energy of 10-35 eV.
- Leucine-enkephalin was injected as a lock mass with a capillary voltage of 3 kV.
- the data was recorded using the MassLynx TM (Waters) program.
- the associated TargetLynx TM program was used to quantify DS50 with the following settings: Quantification fragment, 543.1010; Retention time, 13.0215 min; Retention time window, ⁇ 1 min. Serial dilutions of DS50 in methanol were used as the quantification standard.
- protein concentrations were first determined using the Bradford assay. The proteins were precipitated with 10% (v / v) ice-cold trichloroacetic acid overnight at 4 ° C and then centrifuged (16,100 xg, 20 min, 4 ° C,). The protein pellets were incubated with 0.3 ml of ice-cold acetone at -20 ° C for 30 min, recentrifuged and the supernatant discarded. The pellets were briefly washed twice with acetone, allowed to dry and resuspended in 50 mM triethyl ammonium bicarbonate buffer. The protein concentration were adjusted to 1 mg / ml using the highest concentration fraction.
- the proteins Prior to tryptic digestion, the proteins were reduced with 10 mM dithiothreitol (1 h, 60 ° C) and alkylated with 5 mM iodoacetamide (15 min, 25 ° C). Trypsin (Promega) was added in an enzyme to substrate ratio of 1: 100 and the proteins were digested overnight at 37 ° C with gentle shaking. The tryptic digest was terminated with 1 ⁇ M trifluoric acid and a Hi3 quantification standard was added (PhosB Peptide, Waters, final concentration 12.5 fmol / ⁇ ). Protein identification by mass spectrometry was performed as described below.
- B. subtilis was grown to an OD500 of 0.35 in BMM and treated with 3 ⁇ g / ml DS50 or 12 ⁇ g / ml biotin-DS50 for 15 min or left untreated as a control.
- concentrations were used for the reference antibiotics: 0.15 ⁇ g / ml nocathiacin I, 8 ⁇ g / ml GE2270 A or 50 ⁇ g / ml kirromycin.
- Radiolabeling of newly synthesized proteins during antibiotic treatment with 35 S-methionine and 2D-PAGE analysis were performed essentially as previously described 38 .
- Protein spots were excised from the gel and decolorized twice in wash solution (20 mM ammonium bicarbonate, 30% acetonitrile). Disulfide bridges in proteins from gel pieces recovered from 1D PAGE gels were reduced with 10 mM DTT in wash solution at 60 ° C. for 45 min. The alkylation of cysteines was then performed with 50 mM iodoacetamide (IAA) in washing solution for 25 minutes at room temperature in the dark. The gel pieces were washed twice with washing solution for 5 minutes at room temperature. The reduction and alkylation steps were omitted for samples from 2D PAGE experiments.
- IAA iodoacetamide
- Tryptic peptides were then run from a NanoACQUITY UPLC® CSH130 C18 column (pore size, 130 ⁇ , particle size, 1, 7 ⁇ m, length, 100 mm, Waters) at a flow rate of 0.35 ⁇ / min at 40 ° C using the following Gradients eluted.
- the collision energy was raised from 14 to 45 eV.
- leucine-enkephalin was injected with a capillary voltage of 3 kV every 60 seconds.
- the mass spectra were processed with ProteinLynx Global Server (Waters, version 2.5.2). The processing parameters were adjusted as follows: chromatographic peak width, automatic; MS TOF resolution, automatic; Lock mass for cargo 1, 556.2771 Da / e; Mass window, 0.25 Da; Low energy intensity threshold, 50 counts; Intensity limit at high energy, 15 counts; Intensity limit, 500 counts.
- chromatographic peak width automatic
- MS TOF resolution automatic
- Lock mass for cargo 1 556.2771 Da / e
- Mass window 0.25 Da
- Low energy intensity threshold 50 counts
- Intensity limit at high energy 15 counts
- Intensity limit 500 counts.
- a database of 4180 proteins from B For protein identification, a database of 4180 proteins from B.
- subtilis was used (NCBI reference sequence: NC 000964.3, added manually: trypsin, keratin, quantitation standard PhosB). The following settings were used: peptide tolerance, automatic; Fragment tolerance, automatic; Min. Fragment ions per peptide, 2; Min. Fragment ions per protein, 6; Maximum protein mass, 300,000; Primary digestion reagent, trypsin; Secondary digestion reagent, none; Missed interfaces, 1; Fixed modifications, carbamidomethyl C; Variable modifications, deamidation N, deamidation Q, oxidation M; False positive rate, 4; Concentration of the quantification standard, 50 fmol.
- a template-based synthetic approach described by Liu et al. was used to obtain one of the first Re (I) -Carben complexes was modified. 7
- This approach allows the formation of a carbene unit from rhenium-bound CO ligands.
- 2-azidoaniline was used with triphenylphosphine to form phosphinimine 2a.
- This reacts again with Re (CO) 5 Br at room temperature to convert one of the rhenium-bound CO ligands into a benzimidazol-2-ylidene ligand, yielding the neutral Re (I) carbene complex 3a in good yield ( Figure 1).
- the phosphinimine 2a is stable in air and at room temperature for several weeks.
- the ⁇ NMR spectrum of Figure 3a shows a characteristic signal for the resulting carbene NH protons at 10.4 ppm, which suggests the formation of the symmetrical N-unsubstituted carbene. Furthermore, the aromatic protons are now recognizable as a set of two signals at 7.57 and 7.40 ppm. The successful formation of this structure is further supported by 13 C NMR spectroscopy, which reveals the carbene C atom at 171.9 ppm. The successful preparation of the target compound could also be confirmed by crystal structure analysis.
- Crystals of the cationic complexes 4a, 5a, 6a and 4b and 4c were obtained by slowly evaporating a solution of the complexes in a mixture of dichloromethane and hexane or by slow diffusion of ether into a methanolic solution.
- the molecular structures of bipyridine-containing complexes are shown in Figure 5.
- the structures obtained prove the facial arrangement of the CO ligands in the reaction with the corresponding bisimine ligands.
- the former Re bound bromide atom is found as a counterion of the cationic complexes. All complexes show distorted octahedral geometry.
- Example 3 Absorption and Emission Properties As one would expect for many d 6 -Re (I) (CO) 3 complexes, the carbene complexes show extensive photophysical behavior, which has attracted considerable attention in recent years. The present results are summarized in Figure 6.
- the complexes tested behave very similar and have very pronounced and intense absorption bands in the UV range at about 280 nm with extinction coefficients of about 10 4 dm 3 M "1 cm " 1 ( Figure 7, left). These bands are attributed to the intense intraligand transitions of the bisimine ligands (LC, ⁇ - ⁇ *) and are often found in Re (I) (CO) 3-bisimine complexes. The less intense absorption bands of about 330 to 450 nm with extinction coefficients of 10 3 dm 3 M "1 cm “ 1 are likely to result from MLCT transitions (d (Re) ⁇ n * (bisimine)). 43 '44
- the activity of the compounds can be enhanced to some extent by increasing the lipophilicity (eg row a ⁇ b, 4a ⁇ 5a ⁇ 7a and 4b ⁇ 5b ⁇ 5c).
- too high lipophilicity can lead to reduced activity.
- 7c is the most lipophilic compound, it is less active than 7b and 7a (7c ⁇ 7b ⁇ 7a).
- 7c is the most lipophilic compound, it is less active than 7b and 7a (7c ⁇ 7b ⁇ 7a).
- S. aureus ATCC 3300 seems to be the bathophenanthroline-containing complexes (c) to be able to withstand much better than the other strains.
- Example 5 Spectrum of antibacterial activity of DS50 and biotin-DS50
- DS50 was selected by way of example.
- Biotin-DS50 a biotinylated derivative of DS50 (Biotin-DS50) was prepared and used.
- MIC minimum inhibitory concentration
- the MIC of DS50 and its biotinylated derivative was measured against a set of Gram-negative and Gram-positive bacteria using a standard microtiter plate assay.
- DS50 showed weak or no activity against Gram-negative bacteria but was effective against Gram-positive bacteria with MICs in the low ⁇ g / ml range ( Figure 9).
- the MIC against methicillin-resistant Staphylococcus aureus (MRSA) was 4 ⁇ g / ml.
- Biotinylation of DS50 for target identification studies by immobilization results in a slight reduction in antimicrobial activity, but this compound was still active against Gram-positive bacteria (16-32 ⁇ g / ml). Therefore Biotin-DS50 was used for target identification experiments. It remains unexplained whether the slight decrease in antibacterial activity is due to a reduced uptake of biotin DS50 or interference with target interaction.
- Biotinylated DS50 was immobilized on Strep-Tactin® Sepharose material and incubated with cytosolic cell extract of the Gram-positive bacterium Bacillus subtilis. Unbound proteins were removed by washing and proteins bound to biotin-DS50 were eluted by boiling in SDS-PAGE sample buffer. As controls Strep-Tactin® Sepharose was incubated with biotin, with non-biotinylated DS50 or without compound. The elution fractions were separated by SDS-PAGE and the proteins visualized by RuBPs staining (Figure 10). Compared to the controls, a very prominent protein band is detected on immobilized biotin DS50 identified as elongation factor Tu (EF-Tu).
- EF-Tu elongation factor Tu
- EF-Tu Two bands that co-eluted to a lesser extent and could be additional target proteins or interaction partners of EF-Tu are the chaperone subunit GroEL and the Elongation factor Ts (EF-Ts). It is known that the nucleotide exchange factor EF-Ts interacts with EF-Tu. A direct interaction between GroEL and EF-Tu has not yet been demonstrated. Additional bands that appear in all samples are likely to be naturally biotinylated proteins that can bind directly to the material.
- Example 7 The mechanism of action of DS50 and biotin-DS50
- DS50 was incubated with a B. subtilis cytosolic protein extract or with buffer. Both samples were separated by native ion exchange chromatography and 96 fractions were collected for each run. DS50 was quantified in the collected fractions using LC-MS to identify protein bound (DS50 + cell extract) and free DS50 (incubated with buffer). Incubation of DS50 with the cell lysate resulted in a shift in the retention time compared to the free drug ( Figure 11).
- the proteome of a cell is specifically adapted to counteract and survive stress.
- the upregulated proteins are very specific for the mode of action of the antibiotic 39 used .
- comparison of the B. subtilis proteome profile after treatment with DS50 or biotin-DS50 may provide insight into whether the mechanism of action is altered by biotinylation.
- B. subtilis was treated with DS50 or left untreated as a control. Newly synthesized proteins were radiolabelled and separated by 2D gel electrophoresis on the basis of the isoelectric point and the molecular weight in the first and second dimension, respectively.
- Radiolabelled proteins were visualized and false-color images of the gels of a control and a sample after antibiotic treatment were overlaid (Figure 12).
- marker-proteins were defined by software-supported analyzes, which were at least two-fold upregulated in all biological replicates after antibiotic treatment, and identified by mass spectrometry. Although more marker proteins are up-regulated after treatment with biotin-DS50, both substances show one high agreement of the marker proteins. In addition, many of the marker proteins are also up-regulated for DS50 after biotin-DS50 treatment, but do not reach the strict limit. This shows that biotinylation preserves the mechanism of action in principle.
- Example 8 Proteome analysis to determine the mode of action
- DS50 has the same mode of action as well-characterized EF-Tu inhibitors
- further comparative proteome analyzes were performed.
- the most widely studied EF-Tu antibiotics are the thiazolyl peptides Nocathiacin I and GE2270 A and the structurally unrelated Kirromycin.
- Nocathiacin I binds to the ribosome and inhibits GTP hydrolysis of EF-Tu and other GTP-dependent translation factors 40 .
- GE2270 A inhibits the binding of EF-Tu to Phe-tRNA phe 41 and the formation of a complex of kirromycin with EF-Tu * GDP * aatRNA blocks the detachment of the elongation factor from ribosome 42 .
- proteome analyzes were carried out as described above.
- the proteome response to DS50 was compared to the response to antibiotics known to interfere with EF-Tu activity ( Figure 13).
- DS50, nocathiacin I, GE2270 A and kirromycin show very different proteome profiles, which reflects the different modes of action.
- protein biosynthesis decreases to -15% (data not shown) compared to control conditions and many ribosomal proteins and elongation factors, such as EF-Tu (TufA) and EF-G (FusA) are up-regulated.
- protein biosynthesis is reduced to -65% and only a few marker proteins are up-regulated, of which only the enzyme QueF is associated with translation.
- Protein biosynthesis was unaffected by kirromycin, and the proteome proficiency mainly shows the induction of proteins involved in protein quality control, such as the chaperones DnaK and GrpE or the protease subunits ClpC and ClpP.
- B. subtilis Treatment of B. subtilis with DS50 reduces protein biosynthesis to -67% and 21 marker proteins are induced. Like kirromycin, DS50 induces marker proteins required for protein quality control, but the induced proteins are diverse and include the chaperone system GroESL and the protease subunits ClpY and ClpP. Overall, the proteomic profile of DS50 does not match that of the reference antibiotics, indicating that the mode of action is different. In addition, only DS50 treatment leads to the induction of PspA, a marker protein for membrane stress and YuaE that is up-regulated in response to membrane-active antibiotics. In addition, DS50 has lytic effects on B. subtilis cells in higher concentrations (data not shown).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017115215.6A DE102017115215A1 (de) | 2017-07-07 | 2017-07-07 | Ef-tu-bindendes metallhaltiges antibiotikum |
PCT/EP2018/066100 WO2019007664A1 (de) | 2017-07-07 | 2018-06-18 | Ef-tu-bindendes metallhaltiges antibiotikum |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3649140A1 true EP3649140A1 (de) | 2020-05-13 |
Family
ID=62712976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18733554.2A Withdrawn EP3649140A1 (de) | 2017-07-07 | 2018-06-18 | Ef-tu-bindendes metallhaltiges antibiotikum |
Country Status (4)
Country | Link |
---|---|
US (1) | US11267831B2 (de) |
EP (1) | EP3649140A1 (de) |
DE (1) | DE102017115215A1 (de) |
WO (1) | WO2019007664A1 (de) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2624470B2 (ja) | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
WO1996024606A1 (en) | 1995-02-09 | 1996-08-15 | University Of Washington | Modified-affinity streptavidin |
US6022951A (en) | 1995-04-11 | 2000-02-08 | Univ Boston | Streptavidin mutants |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
AU6701498A (en) | 1997-03-14 | 1998-09-29 | Trustees Of Boston University | Multiflavor streptavidin |
AU2007353319A1 (en) * | 2006-11-15 | 2008-11-20 | Invitrogen Dynal As | Methods for reversibly binding a biotin compound to a support |
EP2226329B1 (de) | 2009-03-02 | 2013-07-10 | Ruhr-Universität Bochum | Metallhaltige Platensimycin-Analoge |
-
2017
- 2017-07-07 DE DE102017115215.6A patent/DE102017115215A1/de not_active Withdrawn
-
2018
- 2018-06-18 WO PCT/EP2018/066100 patent/WO2019007664A1/de unknown
- 2018-06-18 EP EP18733554.2A patent/EP3649140A1/de not_active Withdrawn
- 2018-06-18 US US16/629,044 patent/US11267831B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2019007664A1 (de) | 2019-01-10 |
US11267831B2 (en) | 2022-03-08 |
US20200199162A1 (en) | 2020-06-25 |
DE102017115215A1 (de) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Scheerder et al. | Urea-derivatized p-tert-butylcalix [4] arenes: neutral ligands for selective anion complexation | |
DE68927886T2 (de) | Terpyridin-derivate | |
Shi et al. | Simple-structured, hydrazinecarbothioamide derivatived dual-channel optical probe for Hg2+ and Ag+ | |
Colina-Vegas et al. | Ru (II)/clotrimazole/diphenylphosphine/bipyridine complexes: Interaction with DNA, BSA and biological potential against tumor cell lines and Mycobacterium tuberculosis | |
DE69522490T2 (de) | Platinkomplexe | |
Leitao et al. | Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis | |
Sharma et al. | Synthesis, characterization, crystal structure and BSA binding studies of two novel copper (II) complexes:[trans-Cu (en) 2 (H2O) 2](p-methoxycinnamate) 2 and [trans-Cu (en) 2 (H2O) 2](p-nitrocinnamate) 2· 2H2O | |
DE69201141T2 (de) | NMDA-Antagonisten. | |
Fayaz et al. | Multicomponent solid forms of antibiotic cephalexin towards improved chemical stability | |
EP3649140A1 (de) | Ef-tu-bindendes metallhaltiges antibiotikum | |
Vloon et al. | Synthesis and biological properties of side-chain-modified bleomycins | |
DE60215824T2 (de) | Fluorierte nukleophile substitution von alkoholen und reagenzien zur durchführung des verfahrens | |
DE69903974T2 (de) | Anthraquinone antikrebs-arzneimitteln | |
Deng et al. | Ruthenium (II) complexes containing asymmetric ligands: synthesis, characterization, crystal structure and DNA-binding | |
DE69722214T2 (de) | Salze von anionischen komplexen ru(iii), als antimetastatische und antineoplastische mittel | |
Siri et al. | Iron complexes acting as nitric oxide carriers | |
JP6761564B2 (ja) | ナトリウム・グルコース共輸送体2阻害薬のl−プロリン化合物、およびl−プロリン化合物の一水和物および結晶 | |
JP5327751B2 (ja) | 白金錯体化合物およびその利用 | |
Tsang et al. | Rhenium (V)-oxo complexes of neutral and monoanionic tetraazamacrocycles. X-ray structures of trans-oxohydroxo (1, 4, 8, 11-tetraazacyclotetradecan-2-one) rhenium (V) perrhenate and trans-oxohydroxo (1, 4, 8, 11-tetraazacyclotetradecane) rhenium (V) bis (perchlorate) | |
KR101548806B1 (ko) | 신규한 화합물, 이를 이용한 크롬 이온 또는 알루미늄 이온 검출제, 검출방법 및 검출장치 | |
Grabowski et al. | Synthesis of 1-aminoalkanephosphonous acids bearing furan moiety and its stereochemical aspect | |
Yang et al. | Dinuclear gold (III) pyrazolato complexes–Synthesis, structural characterization and transformation to their trinuclear gold (I) and gold (I/III) analogues | |
DE60207242T2 (de) | Neue anionische und neutrale komplexe von ruthenium (ii) mit stickstoffmonoxid | |
DE10201228A1 (de) | 10-Benzyliden-9(10H)anthracenone als neue Inhibitoren der Tubulinpolymerisation | |
DE102010040822A1 (de) | Neue Imidazoliumsalze und darauf basierende Carben-Metallkomplexe zur Verwendung als bioanalytische Marker für Biomoleküle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20201014 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20210225 |